IDEXX Laboratories, Inc. (NASDAQ:IDXX) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Key Points

• Analysts give IDEXX a consensus "Moderate Buy" from 11 firms (7 buys, 4 holds) with an average 1‑year target of $751.00.
• IDEXX beat the quarter with EPS of $3.47 vs. $3.41 and revenue of $1.14B (up 14.3% YoY), and set FY2026 guidance of $14.45–$14.90 EPS (analyst average ~14.64).
• Corporate insiders sold a total of 45,957 shares worth $29.86M in the last quarter, and insiders now own about 0.79% of the company.

Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Get Free Report) have earned an average recommendation of "Moderate Buy" from the eleven ratings firms that are currently covering the stock, MarketBeat.com reports. Four analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $751.00.

Several equities research analysts have weighed in on IDXX shares. UBS Group cut their target price on IDEXX Laboratories from $730.00 to $640.00 and set a "neutral" rating for the company in a research note on Tuesday, April 28th. BTIG Research lowered their price target on IDEXX Laboratories from $830.00 to $800.00 and set a "buy" rating for the company in a report on Tuesday, February 3rd. Citigroup assumed coverage on IDEXX Laboratories in a research report on Wednesday, April 15th. They set a "neutral" rating and a $650.00 price objective for the company. Weiss Ratings reaffirmed a "hold (c+)" rating on shares of IDEXX Laboratories in a research note on Monday, April 27th. Finally, Stifel Nicolaus decreased their target price on IDEXX Laboratories from $775.00 to $675.00 and set a "buy" rating on the stock in a research report on Tuesday, March 31st.

Insider Buying and Selling

In related news, Director Sophie V. Vandebroek sold 1,464 shares of IDEXX Laboratories stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $628.62, for a total transaction of $920,299.68. Following the sale, the director directly owned 648 shares of the company's stock, valued at approximately $407,345.76. The trade was a 69.32% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Nimrata Hunt sold 1,758 shares of the company's stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $634.57, for a total transaction of $1,115,574.06. Following the transaction, the executive vice president owned 18,141 shares of the company's stock, valued at approximately $11,511,734.37. This represents a 8.83% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 45,957 shares of company stock worth $29,862,109 in the last quarter. Corporate insiders own 0.79% of the company's stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of IDXX. Earned Wealth Advisors LLC grew its holdings in shares of IDEXX Laboratories by 12.4% during the first quarter. Earned Wealth Advisors LLC now owns 416 shares of the company's stock worth $234,000 after purchasing an additional 46 shares during the last quarter. Meeder Asset Management Inc. increased its position in IDEXX Laboratories by 19.8% in the 1st quarter. Meeder Asset Management Inc. now owns 151 shares of the company's stock valued at $85,000 after acquiring an additional 25 shares during the period. Meeder Advisory Services Inc. increased its position in IDEXX Laboratories by 1.3% in the 1st quarter. Meeder Advisory Services Inc. now owns 1,896 shares of the company's stock valued at $1,066,000 after acquiring an additional 25 shares during the period. Dimensional Fund Advisors LP raised its stake in shares of IDEXX Laboratories by 4.3% during the first quarter. Dimensional Fund Advisors LP now owns 573,332 shares of the company's stock valued at $322,145,000 after acquiring an additional 23,582 shares during the last quarter. Finally, True North Advisors LLC bought a new position in shares of IDEXX Laboratories during the first quarter valued at $793,000. 87.84% of the stock is currently owned by institutional investors.

IDEXX Laboratories Price Performance

Shares of NASDAQ:IDXX opened at $572.20 on Friday. The firm has a 50 day moving average of $585.67 and a 200-day moving average of $649.95. IDEXX Laboratories has a 12 month low of $485.40 and a 12 month high of $769.98. The company has a current ratio of 1.12, a quick ratio of 0.90 and a debt-to-equity ratio of 0.19. The stock has a market capitalization of $45.14 billion, a PE ratio of 42.14, a PEG ratio of 3.37 and a beta of 1.58.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last posted its quarterly earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.41 by $0.06. The business had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.12 billion. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The firm's revenue for the quarter was up 14.3% on a year-over-year basis. During the same quarter last year, the business posted $2.91 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. On average, equities research analysts predict that IDEXX Laboratories will post 14.64 EPS for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc NASDAQ: IDXX is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX's product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.